Budesonide ER (Uceris®)

SELF ADMINISTRATION – ORAL

Indications for Prior Authorization:

  • Approvable for induction of remission in patients with active, mild to moderate ulcerative colitis

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of ulcerative colitis

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P&T Committee:

  • All non-FDA approved uses not listed in the approved indications

Recommended Dosing:

  • 9 mg once daily

Duration:

  • Maximum duration of therapy is 8 weeks

Approval: 

Eight weeks


 

Last review date: December 3, 2013